mAbTree Biologics AG

Startup

mAbTree Biologics GmbH, founded in 2019, is a Swiss biotechnology company dedicated to developing innovative monoclonal antibodies for hematological cancers. Our lead product, MT-0002, is a novel, IP-protected, fully human antibody targeting a unique tumor marker. MT-0002 has demonstrated significant preclinical efficacy, including tumor reduction in hematological malignancies such as Myeloproliferative Neoplasms (MPN) and in a colon cancer model.

Key findings include its tolerability in humanized mice, its ability to reduce tumor burden, and its effectiveness in depleting tumor-initiating mutant hematopoietic stem cells (HSCs). This positions MT-0002 as a promising candidate for early-stage eradication of MPN.

These promising results have garnered interest from academic sites in Switzerland, Austria, and Germany for potential clinical trial collaborations. We are currently focused on CMC (GMP manufacturing) activities, aiming for IND submission in 2025. We plan to initiate Phase 1 clinical trials for hematological malignancies, with the potential for orphan drug status, followed by expansion into other malignancies.

With a seasoned leadership team and strong market potential, we believe MT-0002 is poised to become a leading immunotherapy, revolutionizing cancer treatment. We are now actively looking for collaborators from Biotech-Pharma sector and investor circle who would be motivated to foster our efforts in swift clinical development.